NeuroPace reports Q3 EPS (11c), consensus (19c)

Reports Q3 revenue $27.4M, consensus $24.6M. “Our strong third-quarter performance reflects the continued execution of our strategy and the momentum across our business being driven by our team,” said Joel Becker, Chief Executive Officer of NeuroPace (NPCE). “We delivered record revenue growth with strong gross margin, operating and cash discipline while advancing key clinical and product development initiatives that reinforce our leadership in personalized neuromodulation. Our decision to strategically focus our organizational efforts on our differentiated RNS System is reflected in our third quarter results, and with growing awareness of RNS therapy and an expanding base of prescribers, we are encouraged by the progress we are making toward establishing the RNS System as the standard of care in drug-resistant epilepsy.”